Abstract
Berberine, an isoquinoline alkaloid based herbal medicine, is widely used as nutraceutical supplement for the prevention and treatment of various diseases viz. hypolipidemic, hypoglycemic, antiarrhythmic, antineoplastic, etc. The intestinal absorption and oral bioavailability of berberine is very low and almost negligible in humans. In this study, the relative oral bioavailability of berberine was studied, and the effects of The Trivedi Effect®-Energy of Consciousness Healing Treatment on animals and berberine were investigated through the measurement of plasma concentrations after oral administration in rats. The test item, berberine chloride was divided into two parts. One part was denoted as the control without any Biofield Energy Healing Treatment, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment by renowned Biofield Energy Healer, Alice Branton. Additionally, one group of animals also received Consciousness Energy Healing Treatment per se by Alice under similar conditions. Berberine oral formulations were made and administrated by oral gavage at a dose of 150 mg per kg in groups viz. G1 (untreated berberine), G2 (Biofield Treated berberine) and G3 (Biofield Treated animals were received untreated berberine) group. The results showed that berberine had a very low oral plasma exposure of 179.92 ng/mL in the control group. The Biofield Energy Healing Treatment significantly enhanced the relative oral exposure (AUC0–t) of berberine by 233.40% and 35.62% in G2 and G3 groups, respectively compared to the control group. The Biofield Energy Treatment also improved plasma peak concentration (Cmax) of berberine by 37.7 and 1.4 times, in G2 and G3 groups, respectively compared to the control group. The absorption rate constant (Ka) of berberine in Biofield Energy Treatment group significantly increased by 100% (p < 0.05) in G2 group as compared to the control group (G1). The apparent oral plasma clearance of berberine decreased significantly (p < 0.01) by 81%, and 50% in G2 group and G3 group, respectively as compared to the control group. The enhanced bioavailability of berberine might be due to the alteration its physicochemical properties and thermal properties by Biofield Energy Treatment. Biofield Energy Healing Treatment is considered as an innovative strategy which opens new avenues to overcome poorly absorbed drug/nutraceuticals/herbal extracts and can also improve the therapeutic performance of orally active molecules. Thereby, the Biofield Energy Treated berberine chloride having improved bioavailability can significantly increase in antibacterial, anticancer, antidiabetic, anti-obesity, anti-ischemia, memory and cognition, inhibition of metabolic syndrome and neurodegenerative diseases.
Highlights
Berberine, a natural isoquinoline alkaloid obtained from various medicinal herbs such as Coptis chinensis and Hydrastis Canadensis [1]
The absorption rate constant (Ka) of berberine in Biofield Energy Treatment group was significantly increased by 100% (p < 0.05) and 16% in G2 and G3 groups, respectively compared to the control group
The limitation of poor permeability of berberine was successfully overcome using Biofield Energy Healing Treatment (The Trivedi Effect®) by Alice Branton to the test item and rats. The use of this unique Energy Therapy resulted in significant (p < 0.05) increase (233%) in the oral bioavailability and plasma peak concentration (Cmax) by 37.7 folds of berberine in the Biofield Energy Treated groups, compared to the control group
Summary
A natural isoquinoline alkaloid obtained from various medicinal herbs such as Coptis chinensis and Hydrastis Canadensis [1]. Given its relatively safe nature and its numerous pharmacological actions, berberine has a beneficial role in the treatment of human diseases [7,8]. There are seven completed clinical trials on the clinical efficacy of berberine, mainly related to the metabolic syndrome. Berberine has an enormous therapeutic potential as a drug molecule, but it’s poor bioavailability make an obstacle for the development as a clinical candidate. The Cmax of berberine in human plasma was found to be 0.4 ng/mL after a single oral dose of 400 mg [12]. The wide application of berberine is restricted greatly due to its poor intestinal absorption and oral bioavailability. The low oral bioavailability of berberine is primarily due to its properties of low solubility and poor membrane permeability
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
